AUC

Media Advisory: DoseMe Bioinformatician and Chief Science and Strategy Officer Co-Author Abstract Big Data Bayesian Truths to Be Covered in Oral Presentation at the 24th ECCMID Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Health, Infectious Diseases, Hospitals, Health Technology, Genetics, Clinical Trials, Congress, Midwestern University, BCPS, Doctor of Pharmacy, Professor, AUC, Patient, Big data, Vancomycin, Safety, ESCMID, ECCMID, European, Infection, Pharmaceutical industry

ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.

Key Points: 
  • ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.
  • Abstract co-authored Dr. Sharmeen Roy, PharmD, BCPS , Chief Strategy and Science Officer and Paul Sabourenkov , Lead Bioinformatician at DoseMe.
  • What: Abstract 05305, Big Data Bayesian Truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.
  • Details: Title: Big data Bayesian truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

Retrieved on: 
Monday, April 8, 2024
Research, Surgery, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, General Health, Science, Biopsy, Reward, Plasma, International Society, Cohort (statistics), Physician, Risk, AUC, Nucleic acid thermodynamics, Patient, Journal, DNA, Lung transplantation, Heart transplantation, MD, NIH, NTRA, Hospital, Molecule, Bangladesh Technical Education Board, Medicare, Oportunidades, Annual general meeting, NPV

“We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.

Key Points: 
  • “We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.
  • That study showed the Prospera Heart test had an overall area under the curve (AUC) of 0.86 for identifying acute rejection in over 800 samples from 200 adults with heart transplants.
  • The DTRT-2 (DNA-Based Transplant Rejection Test) study, published recently in Pediatric Transplantation , was sponsored by the National Institutes of Health (NIH).
  • A total of 487 samples from 160 heart transplant recipients were evaluated, of which 78 were pediatric and 82 were adult patients.

AvaSure Analytics™ Portal Launches with National Database of Comparative Provider Data

Retrieved on: 
Monday, April 8, 2024
RN, Microsoft, Health, ROI, Organization, Benchmarking, Pressure, Risk, Patient, Hospital, AUC, MSN, Love, Patient safety, Intelligence, Workplace violence, Nursing

BELMONT, Mich., April 8, 2024 /PRNewswire/ -- On the heels of its breakthrough innovation with the AvaSure Episodic solution that allows hospitals to transform their virtual care model, AvaSure has announced significant enhancements to its industry-leading analytics portal that further advances its AI-powered Intelligent Virtual Care platform. The AvaSure Analytics™ portal has been revamped with Microsoft PowerBI tools that enable healthcare providers to conduct deep analysis of critical metrics. As the only comparative database of its kind, AvaSure enables benchmarking an organization's virtual care program performance against more than 800 hospitals nationwide, including a wide range of sizes and types, to drive care quality improvements and return on investment.

Key Points: 
  • The AvaSure Analytics™ portal has been revamped with Microsoft PowerBI tools that enable healthcare providers to conduct deep analysis of critical metrics.
  • "The AvaSure platform has logged over 145 million hours monitoring nearly 2 million patients across the country, consistently delivering program results that improve patient safety while reducing costs," said Adam McMullin, CEO of AvaSure.
  • Amid persistent staffing shortages and rising pressure to control costs, virtual care has become essential for hospitals looking to adapt.
  • To learn more about AvaSure analytics, click here or stop by AvaSure's AONL booth #1112 in New Orleans, April 8-11.

NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digital Health

Retrieved on: 
Monday, March 18, 2024
Nexus, Cloud, Hewlett Packard Enterprise, Azure, GTC, Google Cloud, Health, Metropolis, Patient, History, Orion, LLM, Therapy, San Jose Convention Center, Microsoft, Synthetic media, Vanilla, SAN, Oracle Cloud, 3D, AUC, Protein folding, AWS, Chemistry, Hippocrates, Flywheel, Amgen, Data management, Drug discovery, Acceleration, Hospital, Cadence, AI, Medtech, Dell Technologies, Amazon Web Services, API, CPU, VISTA, Supermicro, Biology, NIM, Universal, Collection, NVIDIA, Generative, Medical device

The microservices, 25 of which launched today, can accelerate transformation for healthcare companies as generative AI introduces numerous opportunities for pharmaceutical companies, doctors and hospitals.

Key Points: 
  • The microservices, 25 of which launched today, can accelerate transformation for healthcare companies as generative AI introduces numerous opportunities for pharmaceutical companies, doctors and hospitals.
  • These include screening for trillions of drug compounds to advance medicine, gathering better patient data to aid early disease detection and implementing smarter digital assistants.
  • “By helping healthcare companies easily build and manage AI solutions, we’re enabling them to harness the full power and potential of generative AI.”
    The new suite of healthcare microservices includes NVIDIA NIM , which provides optimized inference for a growing collection of models across imaging, medtech, drug discovery and digital health.
  • Hippocratic AI is developing task-specific Generative AI Healthcare Agents, powered by the company’s safety-focused LLM for healthcare, connected to NVIDIA Avatar Cloud Engine microservices and will utilize NVIDIA NIM for low-latency inferencing and speech recognition.

Robinhood Markets, Inc. Reports February 2024 Operating Data

Retrieved on: 
Wednesday, March 13, 2024
Crypto, AUC, Robinhood Markets, Net, Cryptocurrency

MENLO PARK, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today reported selected monthly operating data for February 2024:

Key Points: 
  • MENLO PARK, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today reported selected monthly operating data for February 2024:
    Funded Customers at the end of February were 23.6 million, up approximately 130 thousand from January 2024.
  • Assets Under Custody (AUC) at the end of February were $118.7 billion, up 16% from January 2024.
  • Net Deposits were $3.6 billion in February, translating to a 42% annualized growth rate relative to January 2024 AUC.
  • Total Cash Sweep Balances at the end of February were $18.1 billion, up $1.3 billion or 8% from the end of January 2024.

ZOLL Receives Innovative Technology Contract from Vizient for TherOx SuperSaturated Oxygen (SSO2) Therapy

Retrieved on: 
Tuesday, April 2, 2024
Surgery, Medical Devices, Hospitals, Health, Cardiology, Angioplasty, Asahi Kasei, Patient, Cardiac muscle, Facial muscles, Mortality, Splenic infarction, AUC, STEMI, LAD, Heart, Safety, Patient safety, FDA, Nursing

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has received an Innovative Technology contract from Vizient, Inc. , the nation’s largest provider-driven healthcare performance improvement company.

Key Points: 
  • ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has received an Innovative Technology contract from Vizient, Inc. , the nation’s largest provider-driven healthcare performance improvement company.
  • Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient’s Innovative Technology Program.
  • Through its Innovative Technology Program , Vizient works with customer-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare.
  • Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle.

Adtalem Achieves 97% First-Time Residency Attainment Rate and Growing1

Retrieved on: 
Monday, March 25, 2024
General Health, Health, Continuing, University, Education, Obstetrics, Adtalem Global Education, Gynaecology, American University, Med-Peds, ATGE, Physician, RUSM, AUC, Internal, Black, Student, Orthopedic surgery, Health equity, Nursing

These students and graduates will aid in combating the physician shortage that could exceed 120,000 by 2034.

Key Points: 
  • These students and graduates will aid in combating the physician shortage that could exceed 120,000 by 2034.
  • The success of this year's match reflects the quality of Adtalem's programs and the strong demand for its medical school graduates.
  • For comprehensive lists of residency placements, please visit the AUC and RUSM websites.
  • To learn more about Adtalem’s Match Day 2024, visit the Adtalem Newsroom .

New Findings From Sunbird Bio Reveal Significant Potential of Specific Tau Proteins to Serve as Blood-Based Biomarker for Alzheimer’s Disease

Retrieved on: 
Monday, March 25, 2024
Oncology, Health, Neurology, General Health, Research, Science, Biotechnology, Diagnosis, EV, Brain, Plasma, Conference, Dementia, EVS, CSF, Tau, Alzheimer's disease, Sunbird, AUC, Patient, PET, Biomarker, Traffic barrier, APEX, Cerebrospinal fluid, Protein, Neuron, Trial of the century, Aggregation, DSM-IV codes, Blood, Medical imaging

“These results validate the potential of EV-bound tau proteins to serve as reliable blood-based biomarkers in accurately detecting Alzheimer’s disease,” said John McDonough, executive chair and CEO of Sunbird Bio.

Key Points: 
  • “These results validate the potential of EV-bound tau proteins to serve as reliable blood-based biomarkers in accurately detecting Alzheimer’s disease,” said John McDonough, executive chair and CEO of Sunbird Bio.
  • “This confirmed correlation between EV-bound tau in the blood and tau tangles in the brain combined with the early validation of our new tau assays is incredibly exciting.
  • The Sunbird Bio study being shared at Tau2024 evaluated the potential of EV-bound tau proteins in the blood as a method of directly detecting the tau proteins that aggregate in the brain.
  • They then used Sunbird Bio’s new proprietary tau assays to distinguish between EV-bound and unbound soluble forms of tau in plasma.

New Research Shows the PrecivityAD2™ Blood Test Has High Accuracy Compared to Amyloid PET Scans in Individuals with Cognitive Impairment

Retrieved on: 
Monday, March 18, 2024
Mental Health, Managed Care, Medical Devices, Hospitals, Neurology, Science, Medical Supplies, Clinical Trials, Biotechnology, Health, Health Technology, Health Insurance, Other Science, Research, Radiology, Pharmaceutical, Seniors, Radiation, APS2, Certification, Brain, Alzheimer's disease, Deficit spending, Disease, Memory, AUC, Patient, Ageing, PET, Journal, Apolipoprotein, City, CLIA, Pathology, Medicare, Amyloid, Medical imaging

The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2 (APS2), was 0.94, yielding 88% agreement with brain amyloid status based on a single cut-off value.

Key Points: 
  • The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2 (APS2), was 0.94, yielding 88% agreement with brain amyloid status based on a single cut-off value.
  • The APS2 result was the most robust method among the individual plasma amyloid and tau analytes measured to identify disease.
  • In the published study, the PrecivityAD2 blood test was clinically validated in 583 individuals with cognitive impairment across two independent cohorts.
  • C₂N is working toward obtaining the requisite certification that will permit the PrecivityAD2 test to be available in New York in the near future.

Alafair Biosciences Receives Innovative Technology Contract from Vizient for VersaWrap®

Retrieved on: 
Wednesday, April 3, 2024
Hyaluronic acid, Patient, Tissue, AUC, Patient safety, Injury, FDA

AUSTIN, Texas, April 3, 2024 /PRNewswire/ -- Alafair Biosciences, Inc., a leading innovator in the development and commercialization of medical devices, today announced its flagship product, VersaWrap®, has received an Innovative Technology contract from Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company. The contract, effective April 1, 2024, was awarded based on the recommendation of VersaWrap by hospital experts who serve on one of Vizient's customer-led councils. The contract signifies to Vizient provider customers unique qualities that potentially bring improvement to the healthcare industry.

Key Points: 
  • Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient's Innovative Technology Program.
  • "We are sincerely honored that VersaWrap has been recognized and awarded this distinguished Innovative Technology contract," stated John Joyoprayitno, President & CEO of Alafair Biosciences.
  • "Congratulations to Alafair Biosciences for achieving this peer-designated status," said Kelly Flaharty, senior director contract services and Vizient Innovative Technology Program leader.
  • Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle.